[C:1]([C:3]1[N:8]=[C:7]([C:9]2[CH:10]=[C:11]([C:15]3[C:16]4[C:23]([C:24]([O:26][CH2:27][CH3:28])=[O:25])=[CH:22][N:21](COCC[Si](C)(C)C)[C:17]=4[N:18]=[CH:19][N:20]=3)[CH:12]=[CH:13][CH:14]=2)[CH:6]=[CH:5][N:4]=1)#[N:2].C(O)(C(F)(F)F)=O.[OH-].[Na+]>C(OCC)(=O)C>[C:1]([C:3]1[N:8]=[C:7]([C:9]2[CH:10]=[C:11]([C:15]3[C:16]4[C:23]([C:24]([O:26][CH2:27][CH3:28])=[O:25])=[CH:22][NH:21][C:17]=4[N:18]=[CH:19][N:20]=3)[CH:12]=[CH:13][CH:14]=2)[CH:6]=[CH:5][N:4]=1)#[N:2]Ethyl 4-(3-(2-cyanopyrimidin-4-yl)phenyl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate (17 mg, 0.035 mmol) was treated with TFA (500 μL) and stirred at room temperature for 1 hour. To the resulting mixture was added 1 N sodium hydroxide solution (1 mL) and ethyl acetate (3 mL), then allowed to keep stirring for 30 minutes. The organic layer was separated, and the aqueous layer was extracted with ethyl acetate (×3). The combined organic layers were concentrated under reduced pressure and then purified by chromatography on silica eluting with 60-80% ethyl acetatehexane to give ethyl 4-(3-(2-cyanopyrimidin-4-yl)phenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate. LRMS (ESI) calc'd for C20H15N6O2[M+H]+: 371, found 371. 1H NMR (600 MHz, DMSO-D6) δ 13.04 (bs, 1H), 9.07 (d, J=5.28 Hz, 1H), 8.97 (s, 1H), 8.49 (m, 2H), 8.38 (m, 2H), 7.91 (d, J=7.63 Hz, 1H), 7.72 (t, J 7.63 Hz, 1H), 3.84 (q, J=7.04 Hz, 2H), 0.84 (t, J=7.04 Hz, 3H).